dinutuximab (unituxin) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Dinutuximab and dinutuximab beta are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1576.6120 - $2340.3300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

14,18 | ch14.18 | ch14.18 monoclonal antibody | ch14.18-utc | dinutuximab | dinutuximab beta | hu14.18k322a | mab ch14.18 | monoclonal antibody ch14.18 | unituxin

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue